8501 Background: Non-small cell lung cancer (NSCLC) is incurable in most patients with
locally advanced stage IIIA disease. Previous results indicate that the use of neoadjuvant …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

Background: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage
small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral …

Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

Purpose Nivolumab is a monoclonal antibody that blocks the activation of programmed
death-1 receptor, promoting T-cell activation against cancer cells. Thyroid dysfunction (TD) is a …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …

Background: Although concurrent chemoradiotherapy (cCRT) increases survival in patients
with inoperable, locally advanced non-small-cell lung cancer (NSCLC), there is no …

Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

Importance Encephalitis is a severe immune-related adverse event secondary to treatment
with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) …